Cart
sales@molnova.com
Home - Products - Cell Cycle/DNA Damage - Integrin - ILK-IN-3

ILK-IN-3

CAS No. 6975-75-3

ILK-IN-3( —— )

Catalog No. M22072 CAS No. 6975-75-3

ILK-IN-3 is an inhibitor of integrin linked kinase, and with antitumor activity.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 164 In Stock
10MG 262 In Stock
25MG 471 In Stock
50MG 683 In Stock
100MG 954 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock
Get Quotation Bulk Inquiry Add to Cart

Biological Information

  • Product Name
    ILK-IN-3
  • Note
    Research use only, not for human use.
  • Brief Description
    ILK-IN-3 is an inhibitor of integrin linked kinase, and with antitumor activity.
  • Description
    ILK-IN-3 is an inhibitor of integrin linked kinase, and with antitumor activity.(In Vitro):ILK-IN-3 (compound 4, 10 μM) inhibits DYRK1, GSK3α/β, CDK5/p25 kinase activity to 17%, 51%, 47%, 95%, respectively.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    Integrin
  • Recptor
    Integrin
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    6975-75-3
  • Formula Weight
    232.24
  • Molecular Formula
    C10H12N6O?
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 83.33 mg/mL (358.81 mM)
  • SMILES
    COC1=CC=C(C=C1)N=NC2=C(NN=C2N)N
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Jessica Kalra, et al. Validating the Use of a Luciferase Labeled Breast Cancer Cell Line, MDA435LCC6, as a Means to Monitor Tumor Progression and to Assess the Therapeutic Activity of an Established Anticancer Drug, Docetaxel (Dt) Alone or in Combination With the ILK Inhibitor, QLT0267. Cancer Biol Ther. 2011 May 1;11(9):826-38.
Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog
related products

  • RWJ 50271

    RWJ 50271 is a selective lymphocyte function-associated antigen-1/intercellular adhesion molecule-1(LFA-1/ICAM-1) interaction inhibitor( IC50 of 5.0 μM in HL60 cells).

  • Volociximab

    Volociximab (M200) is an IgG4 monoclonal antibody targeting the α5β1 integrin , with antiangiogenic, antitumor and anticancer activity, inhibits the growth of rabbit VX2 tumors and is used to study solid tumors.

  • BIO-5192

    A potent, highly selective inhibitor of integrin α4β1 (VLA-4) with Kd of <10 pM, IC50 of 1.8 nM.

Sign In Join Free